Literature DB >> 2180981

Effects of growth hormone (GH) on plasma bone Gla protein in GH-deficient adults.

J S Johansen1, S A Pedersen, J O Jørgensen, B J Riis, C Christiansen, J S Christiansen, N E Skakkebaek.   

Abstract

Both deficiency and excess of GH are related to disturbances in calcium metabolism. Bone Gla protein (BGP) is the only specific marker of bone turnover identified in peripheral blood. We, therefore, determined plasma BGP in 21 adult GH-deficient patients treated with biosynthetic human GH in a double blind cross-over study. We also examined 9 patients with acromegaly before and after surgery. The GH-deficient patients had normal initial plasma BGP concentrations, whereas the acromegalic patients had highly significantly increased concentrations (P less than 0.001). During treatment with human GH, plasma BGP (and other nonspecific biochemical markers of bone turnover) increased significantly (P less than 0.001). During placebo treatment plasma BGP showed baseline values. In the acromegalic patients a significant decrease in plasma BGP concentrations was seen 1 week after surgery. The present study suggests that plasma BGP is a useful biochemical marker of the effect of treatment of both GH deficiency and GH excess/disorders.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2180981     DOI: 10.1210/jcem-70-4-916

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

1.  Elite volunteer athletes of different sport disciplines may have elevated baseline GH levels divorced from unaltered levels of both IGF-I and GH-dependent bone and collagen markers: a study on-the-field.

Authors:  A Sartorio; N Marazzi; F Agosti; G Faglia; C Corradini; E De Palo; S Cella; A Rigamonti; E E Muller
Journal:  J Endocrinol Invest       Date:  2004-05       Impact factor: 4.256

2.  Growth hormone treatment in adults with GH deficiency: effects on new biochemical markers of bone and collagen turnover.

Authors:  A Sartorio; A Conti; M Monzani; F Morabito; G Faglia
Journal:  J Endocrinol Invest       Date:  1993-12       Impact factor: 4.256

3.  Growth hormone replacement in adults.

Authors:  S M Shalet; S J Holmes
Journal:  BMJ       Date:  1994-05-21

4.  High prevalence of hypovitaminosis D in Sicilian children affected by growth hormone deficiency and its improvement after 12 months of replacement treatment.

Authors:  A Ciresi; F Cicciò; C Giordano
Journal:  J Endocrinol Invest       Date:  2014-05-01       Impact factor: 4.256

5.  New markers of bone and collagen turnover in children and adults with growth hormone deficiency.

Authors:  A Sartorio; A Conti; M Monzani
Journal:  Postgrad Med J       Date:  1993-11       Impact factor: 2.401

6.  Serum levels of bone Gla protein (osteocalcin, BGP) and carboxyterminal propeptide of type I procollagen (PICP) in acromegaly: effects of long-term octreotide treatment.

Authors:  M Terzolo; A Piovesan; G Osella; A Pia; G Reimondo; C Pozzi; C Raucci; M Torta; P Paccotti; A Angeli
Journal:  Calcif Tissue Int       Date:  1993-03       Impact factor: 4.333

7.  Serum bone Gla protein as a marker of bone turnover in acromegaly.

Authors:  M Marazuela; B Astigarraga; M J Tabuenca; J Estrada; F Marín; T Lucas
Journal:  Calcif Tissue Int       Date:  1993-06       Impact factor: 4.333

8.  Long-term effects of octreotide on markers of bone metabolism in acromegaly: evidence of increased serum parathormone concentrations.

Authors:  P Legovini; E De Menis; F Breda; D Billeci; A Carteri; P Pavan; N Conte
Journal:  J Endocrinol Invest       Date:  1997-09       Impact factor: 4.256

9.  Bone density and turnover in young adult patients with growth hormone deficiency after 2-year growth hormone replacement according with gender.

Authors:  F Rota; M C Savanelli; L Tauchmanova; S Savastano; G Lombardi; A Colao; C Di Somma
Journal:  J Endocrinol Invest       Date:  2008-02       Impact factor: 4.256

Review 10.  Renal effects of growth hormone. II. Electrolyte homeostasis and body composition.

Authors:  G D Ogle; A R Rosenberg; G Kainer
Journal:  Pediatr Nephrol       Date:  1992-09       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.